ORIGINAL ARTICLE
Association of ABCB1 T-129C polymorphism and multiple myeloma risk in Polish population
Submission date: 2018-06-12
Final revision date: 2018-09-27
Acceptance date: 2018-10-17
Publication date: 2019-01-31
Pol J Pathol 2018;69(4):405-409
KEYWORDS
TOPICS
ABSTRACT
The possible interaction between gene polymorphism and cancer risk development is a very interesting issue. The genetic variants of the ATP-binding cassette superfamily B member 1 (ABCB1) are known to be involved in developing cancer risk and individual differences in chemotherapeutic response. Polymorphisms may affect the reduction of the activity and/or expression of important protective cellular proteins. The increased exposure to toxic compounds, including carcinogens is associated with an increased risk of developing cancers. The present study was aimed to evaluate the possible effect of ABCB1 T-129C single nucleotide polymorphism in risk of cancer development in Polish patients diagnosed with multiple myeloma. 91 multiple myeloma patients and 94 healthy controls were enrolled in this case-control study. The ABCB1 T-129C genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). The distribution of particular genotypes between multiple myeloma patients and controls group was not significantly different for T-129C SNP (p = 0.4297). The studied polymorphism does not seem to affect the increased risk of multiple myeloma development.
REFERENCES (36)
1.
Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
2.
Eslick R, Talaulikar D. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician 2013; 42: 684-688.
3.
Martino A, Campa D, Buda G, et al. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia 2013; 27: 1615-1616.
4.
Vincent Rajkumar S. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 999-1009.
5.
Ghafouri H, Ghaderi B, Amini S, et al. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer. Tumour Biol 2016; 37: 7901-7906.
6.
Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009; 23: 1691-1697.
7.
Zhai X, Wang H, Zhu X et al. Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci 2012; 8: 659-671.
8.
Balcerczak E, Panczyk M, Piaskowski S, et al. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis. 2010; 25: 1167-1176.
9.
Li Y, Pang S, Huang W, et al. Novel and functional ABCB1 gene variant in sporadic Parkinson’s disease. Neurosci Lett 2014; 566: 61-66.
10.
Ryu HC, Kwon HY, Choi IK, et al. Analyses of single nucleotide polymorphisms and haplotype linkage of the human ABCB1 (MDR1) gene in Korean. Arch Pharm Res 2006; 29: 1132-1139.
11.
Llaudo I, Colom H, Gimenez-Bonafe P, et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int 2013; 26: 177-186.
12.
Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21: 152-161.
13.
Li H, Krstin S, Wang S, et al. Capsaicin and piperine can overcome multidrug resistance in cancer cells to doxorubicin. Molecules 2018; 23: E557.
14.
Zhao L, Li K, Li W, et al. Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility : a meta-analysis based on 11,339 subjects. Tumour Biol 2013; 34: 1949-1957.
15.
Wang J, Guo X, Yu S, et al. MDR1 C3435T polymorphism and inflammatory bowel disease risk: a meta-analysis. Mol Biol Rep 2014; 41: 2679-2685.
16.
Zhang BB, Xuan C, Deng KF, et al. Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Eur J Cancer Care (Engl) 2013; 22: 617-625.
17.
Pongstaporn W, Pakakasama S, Chaksangchaichote P, et al. MDR1 C3435T and C1236T polymorphisms: association with high-risk childhood acute lymphoblastic leukemia. Asian Pac.
19.
Au A, Aziz Baba A, Goh AS, et al. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother 2014; 68: 343-349.
20.
Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 641-651.
21.
Yin G, Xiao Z, Ni Y, et al. Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population. Tumour Biol 2016; 37: 9549-9554.
22.
Wu H, Liu Y, Kang H, et al. Genetic variations in ABCG2 gene predict breast carcinoma susceptibility and clinical outcomes after treatment with anthracycline-based chemotherapy. Biomed Res Int 2015; 2015: 279109.
23.
Jin SS, Song WJ. Association between MDR1 C3435T polymorphism and colorectal cancer risk: A meta-analysis. Medicine (Baltimore) 2017; 96: e9428.
24.
Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794: 860-871.
26.
1 gene variants, pesticide exposure, and increased risk of DNA damage. Biomed Res Int 2014; 2014: 965729.
27.
Wang Q, Wang J, Gao D, Li J. Inhibition of PAR2 and TRPA1 signals allewiates neuropathic pain evoked by chemotherapeutic bortezomib. J Biol Regul Homeost Agent 2017; 31: 977-983.
28.
Zhang Y, Wang Z, Zhang L, et al. Impact of connexin 43 coupling on survival and migration of multiple myeloma cells. Arch Med Sci 2017; 13: 1335-1346.
29.
Tan EK, Drozdzik M, Bialecka M, et al. Analysis of MDR1 haplotypes in Parkinson’s disease in a white population. Neurosci Lett 2004; 372: 240-244.
30.
Jeannesson E, Albertini L, Siest G, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 2007; 21: 411-418.
31.
Komoto C, Nakamura T, Sakaeda T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 2006; 21: 126-132.
32.
Hu LL, Yu B, Yang J. MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54: 1188-1193.
33.
Liu H, Yang ZK, Li Y et al. ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment. Biomed Pharmacother 2016; 80: 115-120.
34.
Kufelnicka-Babout M, Beata S, Kulig A, et al. The significance of T129C and G2677T polymorphism of the MDR1 gene in ovarian cancer patients. Prz Menopauz 2008; 6: 295-300.
35.
Xu J, Zhang H, Gu Y, et al. Correlation anlysis of CD4 gene polymorphism and blood routine indexes in pigs (Sus scorfa).
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
